07:00 , Sep 14, 2015 |  BC Week In Review  |  Company News

Bioceros, Epirus deal

Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) markets Simponi and Stelara to treat autoimmune diseases. Epirus would not disclose when the company plans to begin clinical testing for the acquired biosimilars. Bioceros B.V. , Utrecht,...
01:19 , Sep 10, 2015 |  BC Extra  |  Company News

Epirus nabs biosimilars in Bioceros takeout

Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS) acquired biosimilars company Bioceros B.V. (Utrecht, the Netherlands) for $14.1 million in cash and stock to be paid over a one-year period. Epirus gains three preclinical candidates: BOW080, a biosimilar of...
08:00 , Mar 2, 2015 |  BC Week In Review  |  Company News

PanGenetics, Bioceros deal

PanGenetics granted Bioceros exclusive, worldwide rights to develop preclinical mAb agonists of CD40 to treat cancer. PanGenetics will receive an upfront payment and is eligible for undisclosed milestone payments. PanGenetics B.V. , Utrecht, the Netherlands...
08:00 , Jan 15, 2015 |  BC Innovations  |  Finance

Consortia cross-talk

There's no doubt that the consortium model is here to stay, but the challenge now is to avoid creating a bureaucracy of committees with duplicate missions and redundancies of effort. The answer might be a...
08:00 , Jan 16, 2014 |  BC Innovations  |  Strategy

Biotech kibbutz

Johnson & Johnson and Takeda Pharmaceutical Co. Ltd. have established a beachhead in Israel by partnering with the government and OrbiMed Advisors LLC to build FutuRx Ltd. , a collectively owned biotech incubator. The incubator...
08:00 , Jan 13, 2014 |  BC Week In Review  |  Company News

Bioceros, J&J deal

Bioceros said its BiocerOX Products B.V. affiliate granted Johnson & Johnson's Janssen Pharmaceuticals Inc. subsidiary exclusive, worldwide rights to develop a mAb directed at an undisclosed immune checkpoint modulator. J&J said the deal includes a...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Company News

Bioceros, 4SC, Genedata, Horizon Discovery cardiovascular, genomics, gene/cell therapy news

The CV genes-at-target consortium led by German Heart Center Munich (Munich, Germany) received a €5.8 million ($7.8 million) grant from the EU's Framework Programme 7 (FP7) to evaluate genomic risk loci for coronary artery disease...